Performance Measure: Hepatitis B Vaccination

National Quality Forum #: None

Description: Percentage of patients with a diagnosis of HIV who completed the vaccination series for Hepatitis B

Numerator: Number of patients with a diagnosis of HIV with documentation of having ever completed the vaccination series for Hepatitis B¹

Denominator: Number of patients with a diagnosis of HIV who had a medical visit with a provider with prescribing privileges² at least once in the measurement year

Patient Exclusions:

1. Patients newly enrolled in care during the measurement year
2. Patients with evidence of current HBV infection (HepB Surface Antigen, HepB e Antigen, HepB e Antibody, or Hep B DNA)
3. Patients with evidence of past HBV infection with immunity (Hep B Surface Antibody without evidence of vaccination)

Data Elements:

1. Does the patient have a diagnosis of HIV? (Y/N)
   
   1. If yes, does the patient have documentation of Hepatitis B immunity or is HBV-infected? (Y/N)
      
      1. If no, is there documentation that the patient has completed the vaccine series for Hepatitis B? (Y/N)

National goals, target, or benchmarks for comparison

This HIV/AIDS Bureau measure aligns with the Sexually Transmitted Infections National Strategic Plan for the United States (2021-2025) Core Indicator 4: Increase proportion of people with hepatitis B infection aware of their infection to 50% by 2025 and 90% by 2030.

The HIV Quality Measures (HIVQM) Module is a tool within the Ryan White HIV/AIDS Services Report portal. It allows recipients to enter aggregate data specific to HRSA HAB Performance Measures. The HIVQM Module allows recipients to conduct point-in-time benchmarking across Ryan White HIV/AIDS Programs that use the module.

Department of Health and Human Services Clinical Practice Guidelines

"Hepatitis B immunization is the most effective way to prevent HBV infection and its consequences. All patients with HIV infection who are susceptible to HBV infection should receive hepatitis B vaccination with one of the available vaccines (see below) (AII) or with the combined hepatitis A and hepatitis B vaccine (AII)."³

Use in other federal programs

This measure is linked to an exact or similar indicator(s) within Healthy People 2030, the National HIV/AIDS Strategy (2022-2025), and the Viral Hepatitis National Strategic Plan – A Roadmap to Elimination for the United States (2021-2025).

References/notes

¹ Patients in the middle of the vaccination series on at the end of the measurement year would not be captured in the numerator in year x. They would, if the series was completed on schedule, be captured in year x+1.

² A "provider with prescribing privileges" is a health care professional certified in his/her jurisdiction to prescribe medications.

³ Panel on Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: Recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America (PDF - 6 MB). Department of Health and Human Services. Available online. Accessed August 2022. L-3.